Prospective Multi-country, Real-world, Multi-arm Study of Treatment PErsistence With RISankizumab in Psoriatic Arthritis (PERIS)
Latest Information Update: 06 Feb 2025
Price :
$35 *
At a glance
- Drugs Risankizumab (Primary) ; Antirheumatics
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms PERIS
- Sponsors AbbVie
- 03 Feb 2025 Status changed from not yet recruiting to recruiting.
- 14 Jan 2025 New trial record